Exelixis Inc Deferred Federal Income Tax Expense (Benefit)
Exelixis Inc (EXEL) reported Deferred Federal Income Tax Expense (Benefit) of $128.46 million for the 12-month period ending 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-02-10
- Exelixis Inc deferred federal income tax expense (benefit) for fiscal 2026 was $128.46M.
- Exelixis Inc deferred federal income tax expense (benefit) for fiscal 2025 was -$52.43M.
- Exelixis Inc deferred federal income tax expense (benefit) for fiscal 2023 was -$123.49M.
- Exelixis Inc deferred federal income tax expense (benefit) for fiscal 2022 was -$54.22M, a 216.82% decline from fiscal 2021.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2026-01-02 | $128.46M 10-K · filed 2026-02-10 |
| 2025-01-03 | -$52.43M 10-K · filed 2026-02-10 |
| 2023-12-29 | -$123.49M 10-K · filed 2026-02-10 |
| 2022-12-30 | -$54.22M 10-K · filed 2025-02-11 |
| 2021-12-31 | $46.42M 10-K · filed 2024-02-06 |
| 2021-01-01 | $14.89M 10-K · filed 2023-02-07 |
| 2020-01-03 | $71.58M 10-K · filed 2022-02-18 |
| 2018-12-28 | -$238.68M 10-K · filed 2021-02-11 |
| 2017-12-29 | $0.00 10-K · filed 2020-02-25 |
| 2016-12-31 | $0.00 10-K · filed 2017-02-27 |
| 2016-12-30 | $0.00 10-K · filed 2019-02-22 |
| 2016-01-01 | $0.00 10-K · filed 2018-02-26 |
| 2015-12-31 | $0.00 10-K · filed 2017-02-27 |
| 2014-12-31 | $0.00 10-K · filed 2017-02-27 |
| 2013-12-31 | -$106.00K 10-K · filed 2016-02-29 |
| 2012-12-31 | $0.00 10-K · filed 2015-03-02 |
| 2011-12-31 | $0.00 10-K · filed 2014-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |